Bone metastases are associated with considerable morbidity, and radiotherapy is widely used for palliation of symptomatic bone lesions. Now, data from a phase II trial performed at three US centres indicate that irradiation of asymptomatic bone metastases not only mitigates skeletal-related events (SREs), but also reduces the risk of death.